Tokumitsu, Keita
Sugawara, Norio
Maruo, Kazushi
Suzuki, Toshihito
Yasui-Furukori, Norio
Shimoda, Kazutaka
Funding for this research was provided by:
Japan Society for the Promotion of Science (15H04754)
Article History
Received: 26 April 2020
Accepted: 11 November 2020
First Online: 18 November 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: NYF has been a speaker for Dainippon Sumitomo Pharmaceutical, Mochida Pharmaceutical, and MSD. KS has received research support from Meiji Seika Pharma Co.; Pfizer Inc.; Dainippon Sumitomo Pharma Co., Ltd.; Daiichi Sankyo Co.; Otsuka Pharmaceutical Co., Ltd.; Astellas Pharma Inc.; Novartis Pharma K.K.; Eisai Co., Ltd.; and Takeda Pharmaceutical Co., Ltd., as well as and honoraria from Mitsubishi Tanabe Pharma Corporation; Meiji Seika Pharma Co., Ltd.; Dainippon Sumitomo Pharma Co., Ltd.; Takeda Pharmaceutical Co.; Shionogi & Co., Ltd.; Daiichi Sankyo Co.; Pfizer Inc.; and Eisai Co., Ltd. The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript. The remaining authors declare that they have no competing interests to report.